CGT Global Appoints Charlotte Ivancic to Board of Advisors, Strengthening Strategic Leadership in Cell and Gene Therapy Policy and Market Access

RENO, Nev.--(BUSINESS WIRE)--CGT Global, a leading accelerator of innovation, implementation and access to cell and gene therapies, announced today the appointment of Charlotte Ivancic to its Board of Advisors. Ms. Ivancic brings more than 25 years of experience at the intersection of federal health policy, legislative strategy, and biopharmaceutical innovation.

A partner at FGS Global, Ms. Ivancic advises organizations on complex healthcare policy, regulatory strategy, and stakeholder engagement. Her career spans senior advisory roles on Capitol Hill, including serving key leadership positions for Senate Majority Leader Bill Frist, House Budget Chairman Paul Ryan, and Speaker John Boehner. During her time on Capitol Hill, she played a key role in shaping Medicare payment policy, including efforts to modernize physician reimbursement and advance value-based care models. She also practiced healthcare law in Washington, D.C. and conducted research at Children’s Hospital Boston and Harvard Medical School.

In moving cell and gene therapies closer to widespread adoption, the industry faces challenges beyond scientific innovation. Long-term scalability will depend on aligning novel treatment models with existing reimbursement frameworks, including managed care, Medicare and Medicaid, while navigating complex legislative and regulatory pathways. Expanding access will require rethinking how and where care is delivered particularly through outpatient models that can reduce cost and improve patient experience.

“Charlotte brings a rare combination of policy expertise and real-world impact,” said Cate Spears, Founder and CEO of CGT Global. “She has helped shape the very reimbursement frameworks that now influence how advanced therapies can scale. As our industry works to reduce cost and expand access, her insight into Medicare, Medicaid, and federal policy will be critical in helping us translate innovation into sustainable care delivery.”

Ms. Ivancic’s expertise in legislative strategy and healthcare systems positions CGT Global to play a more active role in shaping the frameworks needed to support broader adoption of advanced therapies.

“Cell and gene therapies hold enormous promise, but realizing that promise requires more than scientific advancement,” said Ivancic. “It requires thoughtful integration into the healthcare system addressing reimbursement, delivery models, and regulatory process. CGT Global is uniquely positioned to address these challenges, and I’m excited to support their mission to expand patient access.”

Ms. Ivancic currently serves on the Board of Directors of the Alliance for Health Policy, contributing to national discussions on healthcare access, quality, and innovation.

Her appointment to the Board of Advisors reflects CGT Global’s continued investment in building the strategic, clinical, and operational foundation needed to scale cell and gene therapies from breakthrough science to standard of care.

About CGT Global

CGT Global is a leading accelerator of cell and gene therapies, powering innovation, access, and scalability. With a national network of clinical sites and laboratories, CGT Global provides high-quality biospecimens, GMP-compliant manufacturing, and end-to-end support across the therapy lifecycle from early discovery through clinical development and commercialization.

The company is also advancing new models of care delivery, including outpatient treatment approaches designed to reduce cost, improve operational efficiency and expand patient access to advanced therapies. By integrating research, clinical infrastructure, and patient delivery capabilities, CGT Global helps bridge the gap between scientific breakthrough and real-world impact.

Headquartered in Reno, Nevada, CGT Global partners with leading biopharmaceutical companies, CROs, and healthcare institutions to accelerate the future of advanced therapies. Learn more at www.cgt.global